Hospital
Mountain States Health Alliance
Mountain States Health Alliance was paid $11.37M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoMOUNTAIN STATES HEALTH ALLIANCE
LEBANON, VA 24266
LEBANON, VA 24266
33aNPI1891973939assigned 01/31/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.37M
24GClaims316,429
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#47 of 80
Median peer was paid$14.69M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,640 | $1.04M | |
| 2019 | 57,977 | $1.55M | |
| 2020 | 41,580 | $1.37M | |
| 2021 | 44,428 | $1.73M | |
| 2022 | 45,463 | $1.91M | |
| 2023 | 46,970 | $2.15M | |
| 2024incomplete | 32,371 | $1.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 19,826 | 16,929 | $3.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 15,159 | 13,115 | $1.99M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 5,002 | 3,920 | $1.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 8,692 | 7,392 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 2,396 | 2,188 | $496K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 2,605 | 2,280 | $438K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 2,839 | 2,589 | $385K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 1,966 | 1,751 | $383K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.7% | 6,120 | 5,580 | $308K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 2,515 | 1,931 | $205K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 4,149 | 963 | $186K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,033 | 1,587 | $168K |
146 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 1,261 | $130K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 3,126 | $126K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.1% | 685 | $122K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 804 | $111K |
| 80053 | Comprehensive metabolic panel | <1% | 24,214 | $111K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,437 | $107K |
| G0378 | Hospital observation service, per hour | <1% | 953 | $83K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 188 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,854 | $46K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,028 | $45K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,443 | $34K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,055 | $31K |
| 72100 | <1% | 1,264 | $26K | |
| 87040 | <1% | 3,987 | $23K | |
| 73562 | <1% | 1,574 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,590 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,780 | $19K |
| 83880 | <1% | 2,627 | $18K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 72 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,863 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,101 | $15K |
| 73130 | <1% | 1,142 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 144 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,248 | $13K |
| 73610 | <1% | 1,071 | $13K | |
| 80061 | Lipid panel | <1% | 2,472 | $13K |
| 73630 | <1% | 1,151 | $12K | |
| 73030 | <1% | 742 | $12K | |
| 80329 | <1% | 1,135 | $12K | |
| 71250 | <1% | 164 | $12K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,454 | $10K |
| 84484 | <1% | 7,011 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,457 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,130 | $10K |
| 73110 | <1% | 507 | $9K | |
| 82607 | <1% | 1,869 | $9K | |
| J3490 | Unclassified drugs | <1% | 1,610 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,560 | $7K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 50 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 28 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 113 | $6K |
| 97035 | <1% | 107 | $5K | |
| 85027 | <1% | 2,499 | $5K | |
| 82728 | <1% | 1,468 | $5K | |
| 95811 | <1% | 13 | $5K | |
| 74018 | <1% | 428 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 217 | $4K |
| 80320 | <1% | 775 | $4K | |
| 81001 | <1% | 7,358 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 660 | $3K |
| 90715 | <1% | 196 | $3K | |
| 83605 | <1% | 3,159 | $3K | |
| 83550 | <1% | 754 | $3K | |
| 84439 | <1% | 541 | $3K | |
| 12001 | <1% | 13 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,769 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 183 | $3K |
| 83690 | <1% | 5,441 | $3K | |
| 83540 | <1% | 1,394 | $2K | |
| 83735 | <1% | 3,127 | $2K | |
| 86140 | <1% | 990 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,482 | $2K |
| 81003 | <1% | 4,666 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 16 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $2K |
| 85379 | <1% | 432 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 16 | $2K |
| 85610 | <1% | 1,722 | $2K | |
| 73502 | <1% | 151 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,482 | $1K |
| 87088 | <1% | 1,053 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 216 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,604 | $1K |
| 87186 | <1% | 1,177 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 326 | $1K |
| 93971 | <1% | 16 | $1K | |
| 81025 | <1% | 2,435 | $1K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 496 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,072 | $1K |
| 97014 | <1% | 82 | $1K | |
| 82570 | <1% | 359 | $1K | |
| 87077 | <1% | 1,923 | $1K | |
| 80143 | <1% | 503 | $990.95 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,514 | $923.59 |
| 96523 | <1% | 15 | $851.39 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,074 | $805.82 |
| 82043 | <1% | 267 | $666.89 | |
| 85651 | <1% | 433 | $646.52 | |
| 96376 | <1% | 1,718 | $632.83 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,868 | $606.61 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 279 | $593.70 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,726 | $548.40 |
| 97162 | <1% | 41 | $533.43 | |
| 82746 | <1% | 236 | $504.95 | |
| 73080 | <1% | 42 | $498.67 | |
| 80179 | <1% | 492 | $483.40 | |
| 85652 | <1% | 563 | $478.40 | |
| 87522 | Neg quan hep c or qual rna | <1% | 24 | $430.34 |
| 84466 | <1% | 498 | $415.08 | |
| 82140 | <1% | 284 | $385.72 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 42 | $375.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,360 | $324.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,656 | $293.19 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 760 | $261.12 |
| 84703 | <1% | 1,092 | $236.28 | |
| 83615 | <1% | 359 | $235.29 | |
| 84100 | <1% | 286 | $199.31 | |
| 80076 | <1% | 15 | $182.93 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $93.34 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 79 | $91.64 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 904 | $73.27 |
| 87081 | <1% | 751 | $72.64 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,122 | $64.52 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,462 | $61.87 |
| 74022 | <1% | 13 | $57.50 | |
| 85007 | <1% | 81 | $47.22 | |
| 80074 | <1% | 13 | $45.95 | |
| 82803 | <1% | 119 | $30.30 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 13 | $29.83 |
| 82550 | <1% | 136 | $28.68 | |
| 85730 | <1% | 54 | $25.66 | |
| 82533 | <1% | 19 | $22.66 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 390 | $21.13 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 101 | $19.58 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 249 | $16.85 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 323 | $15.72 |
| 85045 | <1% | 15 | $15.51 | |
| 87807 | <1% | 130 | $13.58 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 192 | $12.67 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 95 | $9.42 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 79 | $4.20 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 31 | $3.24 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 50 | $2.95 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 25 | $2.67 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 49 | $1.85 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 19 | $1.13 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 17 | $1.12 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 77 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 76 | $0.00 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 15 | $0.00 |
| 94760 | 0% | 306 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 41 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 78 | $0.00 |
| 82150 | 0% | 17 | $0.00 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILTON, SHANE (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.